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1. Introduction
The occurrence of depression with diabetes mellitus has been intensively researched for a num‐
ber of decades now. It was Thomas Willis (1621 – 1675) who introduced the phrase diabetes
mellitus (before then called Willis’s disease) and associated it with what had already been
known for decades – that patients with diabetes have glycosuria (sweet urine). He also noted
that “sadness or excessive melancholy, similar to fits or other depressions and breakdowns of
the animal spirit, give rise to or instigate this diseased condition (diabetes)”. His follower J. C.
Brunner (1653 – 1727) is known because of several studies with the pancreas. The large number
of epidemiological studies documents the increasing interest in this problem.
Evidence of a bidirectional relationship between depression and diabetes has also been re‐
cently documented in large prospective studies. Comorbid depression is associated with an
increased risk of poor glycaemic control, diabetes complications have also been found to be
risk factors for subsequent development of depressive episodes
The importance of the research on depression and diabetes has been emphasized in recent
years because of the modern-day epidemic of obesity and diabetes that is emerging in both
high and low income countries. The direct medical and indirect personal and familial costs
of this epidemic are starting to get international attention.
2. The epidemiology, risk factors and clinical features of depression and
diabetes
2.1. The epidemiology of depression and diabetes
From the meta-analysis Petrak (2009) it follows that 9% of patients with DM have at the
same time some form of affective spectrum disorder. If we also take the subclinical form of
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depression into consideration, then the number of patients with depression increases to
26%. diabetes mellitus (DM) doubles the risk of the occurrence of depression independently
of the study design, the sample of patients and the methods of evaluating depression. Con‐
temporary knowledge related to type 2 diabetes points out the worsening of depressive dis‐
plays in individuals treated (but not those untreated) for type 2 diabetes. These findings
could reflect stress or an association with management of diabetes and a large number of
diabetic complications and co-morbidities in adults undergoing diabetic treatment in com‐
parison with the untreated. Depressive displays occur in approximately 43 million people
with diabetes, keeping in mind the overall prevalence of diabetes in the year 2000 (Wild et
al., 2004). From the results of the study Sequenced Treatment Alternatives to relieve Depres‐
sion (STAR-D), the largest study relating to depression carried out in the USA, the most
common occurrence of the co-morbidity of depression and diabetes occurs in the elderly
and in minorities (Hispanics and black African-Americans).
Clinically significant depressive symptoms occur in approximately 31% of patients with dia‐
betes, more often in women (in a ratio of 1:1.8); the picture of severe depression (according
to strict diagnostic criteria) occurs in 11% of patients with diabetes. With diabetes the risk of
a depressive disorder arising is approximately 2 times higher than in the common popula‐
tion (OR = 2.0, 95% CI 1.7 – 2.2), independently of the type of diabetes or on the method of
evaluating depressive symptoms (Katon et al., 2004). Approximately 30% of those ill with
diabetes have a depressive disorder (28% of women with diabetes and 18% of men with dia‐
betes – the preponderance of women with depression is similar as in the non-diabetic popu‐
lation). The risk of depression arising in patients with diabetes, whether insulin dependent
or not, is higher by 15 – 20%. Depressive displays in the common population occur approxi‐
mately in the age range from 27 to 35 years, but in patients with diabetes this already begins
around the 22nd year. The relationship between demographic parameters, lifestyle and be‐
haviour, anti-depressive treatment, BMI, diagnosis of diabetes, its duration and treatment
and depressive symptoms were tested in 70,000 patients. Diabetes was identified in 21.7%
and had a link with depressive symptoms (AOR, 1.24; 95% CI, 1.14-1.34). Demographic pa‐
rameters, lifestyle and behaviour, BMI and anti-depressive treatment were more strongly
linked with serious depression than a diagnosis of diabetes (Osborn et al., 2011). In a report,
Gendelman et al. (2009) showed that prevalence rates were even higher if reports of elevated
symptoms were combined with the use of antidepressant medication. This suggests that the
available evidence should be considered with particular methodological differences in case
ascertainment kept in mind.
In people diagnosed with type 1 or type 2 diabetes, depression increased the risk of lin‐
gering hyperglycemia,  microvascular  and macrovascular  complications and overall  mor‐
tality  (Barnard  et  al.,  2006;  Ismail  et  al.,  2007).  It  is  interesting  that  complications  and
mortality  in  connection  with  diabetes  are  also  observed  even  with  less  serious  depres‐
sive displays.  Older patients appear as a high-risk group, which is  also reported by the
result of a 7-year longitudinal study, which shows a five-fold growth in mortality with‐
out  any  significant  differences  of  the  impact  of  the  seriousness  between  moderate  and
heavy displays of depression (Black et al., 2003).
Mood Disorders24
2.2. Clinical symptoms
Depression is usually defined by the number of symptoms present, usually within the past
two weeks. In order to diagnose major depression using DSM-IV or ICD-10 criteria, a clini‐
cal interview is conducted and a number of symptoms have to be present (table 1). Most epi‐
demiological research on the prevalence of depression uses self-report instruments (for
example Patient Health Questionnaire-9- PHQ-9 ) for detecting depression or depressive
symptomatology, and most instruments that are used measure symptoms that approximate
clinical levels of disorder (table 1). The specific symptoms for depression and diabetes are
little difference as only for depression alone (table 2), (Lloyd et al., 2010).
DSM-IV criteria(at least five symptoms present nearly every day for 2 wk and causing significant distress or
functional impairment
Depressed mood
Markedly diminished interest or pleasure in all or almost all activities
Significant weight loss/gain or decreased/increased appetite
Insomnia or hypersomnia
Psychomotor agitation or retardation
Fatigue or loss energy
Feelings of worthlessness/guilt
Diminished ability to concentrate/make decisions
Recurrent thoughts of death or suicide
Symptoms of depression measured using self-report instruments
Feeling sad/depressed mood
Inability to sleep
Early waking
Lack of interest/enjoyment
Tiredness/lack of energy
Loss of apetite
Feelings of guilt/worthlessness
Recurrent thoughts about death/suicide
DSM-IV criteria extracted from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision,
Copyright 2000. American Psychiatric Association
Table 1. Symptoms listed in the DSM-IV criteria for major depressive disorder and symptoms of depression measured
using self-report instruments
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Fatigue
Loss of weight, poor apetite
Psychomotor retardation
Insomnia
Pain
Gastrointestinal problems
Table 2. Common symptoms for depression and diabetes (free by Montano, 2004)
Salomé et al. (2011) evaluated the seriousness of depressive symptoms in patients with a di‐
abetic ulcer of the shin area and determined that in 41 patients out of 50 depressive symp‐
toms were present and in 32 of them found displays of moderate-severe depression with
reduced self-evaluation, anorexia, disfigured body-image and a worse libido.
2.3. Risk factors associated with depression and with diabetes
Quality of life is worsened in regard to psychological, physical and social functioning (e.g.
ability to work). Complications caused by diabetes are considered as the most serious, and
treatment of diabetes is significantly more complicated and worse if depression is present at
the same time. In a recent study patients with depression and diabetes were physically less
active, smoked more, had fewer healthy dietary habits and were less inclined to diabetic
treatment (Gonzales et al., 2008). Depression during diabetes, despite everything, often goes
undiagnosed and untreated. In an American study, in which more than 9000 patients with
diabetes took part – 51% of which had identified depression – only 43%of them used one or
more antidepressants and only 7% took part in four or more psychotherapeutic meetings
during a 12-month period (Katon et al., 2004).
2.3.1. Risk factors for depression in patients with diabetes
Through a number of epidemiological studies, aside from the prevalence of depression in
patients with diabetes, it was also possible to identify a number of risk factors which are
more or less associated with depression. These are the risk factors – demographic (female
sex, younger age, lower education, poverty), clinical (seriousness of diabetes, duration of ill‐
ness, complication of diabetes, high values of glycosylated HbA1c) and behavioral (smok‐
ing, obesity) (table 3). Their importance in relation to depression, however, is continuously
being verified (Egede & Zheng, 2003). In connection with the presented results it was shown
that the most significant association exists between depression, obesity and smoking. Obesi‐
ty positively correlates with the growing prevalence of type 2 diabetes. It has been shown
that smoking associates with increased insulin resistance and represents a risk factor for
macrovascular complications in patients with diabetes mellitus. But we know that depres‐
sion also increases the risk of smoking, which has been documented in several longitudinal
studies in which it was confirmed that there are notably more smokers in the group of pa‐
tients with depression than in the control group (Katon et al., 2004). In the study of Fisher et
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al., 2011, in a group of more than 480 patients it was compared whether patients educated
about regular observation of glucose monitoring, treatment and regimen also have better re‐
sults in association with HbA1c and with glucose, which also confirmed at the same time
the fact that improved depressive symptoms were not dependent on improved metabolic
parameters or glucose. In a pilot randomized controlled study integrated treatment of type 2
diabetes and depression was more successful versus common treatment in improved HbA1c
results and depression in older, perhaps 60 Afro-Americans. It follows from this that inte‐
grated treatment could be available and effective in real conditions taking into consideration
certain limitations.
Although depression is not a part of normal ageing, prevalence rates of severe depressive
episodes/major depressive disorder are higher amongst certain groups of older people, in
particular, individuals with a co-morbid medical illness (Kovacs et al., 1997). However, to
date, little epidemiological data has been available with which to examine rates of depres‐
sion in older people with diabetes (Collins et al., 2009). To further complicate the picture,
several studies have reported that depressive symptoms are more common in younger indi‐
viduals, in both type 1 and type 2 diabetes (Fisher et al., 2008). Collins et al. (2009) also re‐
ported lower rates of depression in older individuals with type 1 diabetes, suggesting that
age might have a protective effect. In a cohort of patients aged 70 -79 years followed for
about six years, those with diabetes had an increased level of depression with attenuated af‐
ter adjustment for diabetes-related co-morbidities, although this still represented a signifi‐
cantly increased risk compared to controls. In this study, HbA1c was a predictor of
recurrent depression (Maraldi et al., 2007). The specific factors associated with recurrence of
depression remain unclear. Gender has not been found to be associated with the number of
episodes or the severity of recurrence or chronicity of depression, and the association be‐
tween stress and depressive episodes appears to be less pronounced over time (Stroud et al.,
2008). There is some evidence of a link between depression and the occurrence of diabetic
complications and poorer glycaemic control. Painful neuropathy may be another trigger for
depression. Diabetes can cause small vessel pathology in the brain that leads to subcortical
encephalopathy, not unlike that seen in vascular depression. This may lead to both cognitive
impairment and depressed mood (Baldwin, 2010).
Non-diabetic specific risk factors Diabetes specific risk factors
Female gender Manifestation of diabetes
Lack of social support Occurrence of late complications
Low socioeconomic status Persistent poor glycaemic control
Younger age; older age and physical health problems Need for insulin therapy in type 2 diabetes
Occurrence of critical life events Hypoglycaemia problems
Table 3. Risk factors for depression in diabetes
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2.3.2. Depression - a risk factor for diabetes?
The link between depression and diabetes was made as early as the seventeenth century, when
the famous English physician T. Willis (1621 -1675) noted that diabetes often appeared among
patients who had experienced significant life stresses, sadness or long sorrow (Rubin & Peyr‐
ot, 2002). Whether depression increases the risk of type 1 diabetes is currently unknown. How‐
ever, recent studies have suggested that people with depression are more vulnerable to the
development of type 2 diabetes (Mezuk et al., 2008), thereby confirming Willis´ hypothesis. It
is important to recognize that depression is not only associated with an increased risk for the
development of type 2 diabetes, but is also an established risk factor for cardiovascular dis‐
ease and several features of the metabolic syndrome, particularly hypertension, abdominal
obesity and low HDL cholesterol (Vogelzangs et al., 2008). Several hypotheses have been put
forward regarding the pathophysiological mechanisms that could explain the increased risk of
type 2 diabetes in depressed subjects. For example, increased activity of the hypothalamic-pi‐
tuitary-adrenal (HPA) axis and sympathetic nervous system might play a role; there are exam‐
ined elsewhere in this volume (Lloyd et al., 2010).
Figure 1. Pathophysiological abnormalities in HPA axis hyperactivity, which in response to elevated levels of CRH,
ACTH production and secretion is increased, it stimulates the adrenal cortex to secrete cortisol, and cortisol concentra‐
tions inhibit secretion only other hormons, but it is also a signal for the (no) supersaturation
Depression may also increase the risk for type 2 diabetes via behavioural mechanisms. It is
well known that the most important risk factor for type 2 diabetes is obesity, and that physi‐
cal inactivity further increases this risk (Manson et al., 1991). Finally, the evidence to date
suggests that depression may indeed increase the risk of developing type 2 diabetes. How‐
ever, the mechanisms via which this may occur still require investigation. The link between
depression and the development of type 1 diabetes remains unclear.
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Anxiety is common in diabetes populations and is frequently associated with depression
(Katon et al., 2007). A recent systematic review found that around 14% of people with diabe‐
tes have generalized anxiety disorder, but subclinical anxiety and symptoms were more
common and affected 27% and 40% respectively (Grigsby et al., 2002). The presence of co‐
morbid depression or anxiety has been associated with increased somatic symptoms of dis‐
ease, which has important implications for treatment (Katon et al., 2007). Diabetic-specific
psychological problems, such as fear of self-injecting insulin or self-testing blood glucose
(which may or may not be full-blown needle phobia) and fear of complications, are all asso‐
ciated with anxiety and depression (Mollema et al., 2001). Fears regarding hypoglycaemia
and psychological insulin resistance are also common, but their relationship with depression
is less clear (Petrak et al., 2007).
3. The common pathophysiological mechanisms of depression and
diabetes
Many etiological factors play a role in the pathophysiology of depression. Among them are
the depletion of serotonin and other monoamines in areas of the brain which are connected
with the managing of emotions, sleep and the taste for food. Another factor is the chronic
activation of the hypothalamic-pituitary-adrenal axis with subsequent increased production
of a corticotropic hormone (CRF). Depression can also originate as a consequence of insuffi‐
cient plasticity of neurons as a response to different burdens, e. g. chronic stress (Wayne et
al., 2004). Genetic influences also apply with depression and metabolic syndrome as well as
unfavorable factors from the external environment. Among these, for example, are disorders
of equilibrium in the autonomic nervous system with an inclination toward more rapid
heart activity, reduced variability of heart frequency and increased level of catecholamines
in peripheral blood. According to one of the theories of development of metabolic syn‐
drome, an improper daily regimen (especially low physical activity during the day and in‐
take of food in the late night hours) leads to disorders of equilibrium in the autonomic
nervous system, with a preponderance of the sympathetic system in the area of the thorax
and in the skeletal muscles, with a subsequent increase in blood pressure, insulin resistance
in the muscles and, in contrast, to increased activity of the parasympathetic system in the
stomach area, which leads to hyper secretion of insulin and the accumulation of visceral fat‐
ty tissues, which can lead further to increased risk of origin of metabolic syndrome, type 2
diabetes, dyslipidemia, hypertension and visceral obesity (Zeman & Jirák, 2008). In patients
with a metabolic syndrome, as well as in patients with depression, oxidation stress is shown
to be increased with subsequent destruction of neurons in the hippocampus, whose smaller
volume we find also in patients with depression (Sapolsky, 2000). An association between
symptoms of depression and metabolic syndrome was shown in a study tracking pairs of
male twins (McCaffery et al., 2003). In the population tracked in NHANES III (Third Nation‐
al Health and Nutrition Examination Survey) the prevalence of metabolic syndrome among
women with depression was double that of women without depression (Kinder et al. 2004).
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In the study of Poulsen et al. (2001) 303 older twins were tracked, and significantly higher
glucose intolerance was found along with obesity and low HDL-cholesterol among monozy‐
gotic versus dizygotic twins, which shows the genetic impact on the development of these
phenotypes. They observed a higher genetic influence on glucose intolerance and systolic
pressure and a lower genetic influence on low HDL-cholesterol and diastolic pressure in
male twins versus female twins. Pouwer & Snoek (2001) observed in more than 1500 pa‐
tients for the first time significant associations between depression and HbA1c in women
with type 2 diabetes. The values of estrogen and the daily regimen could play a significant
role in these associations.
With type 1 diabetes the development of an endocrine disorder precedes the first episode of
depression. Anderson et al. (2001) in a meta-analysis of 27 clinical studies (a total of 5370
patients) found a statistically significant relationship between depression and diabetic com‐
plications (diabetic retinopathia, nephropathia, neuropathia, macrovascular complications
and sexual dysfunction) (p<0,0001, z=5,94). Pro-inflammatory cytokines also show a clear as‐
sociation of both disorders (Tůma, 2005). Cytokines, interleukins and TNF alpha are in‐
creased with both disorders and can associate with some depressive displays (Tůma &
Hubeňák, 2007).
From a biological point of view depression and diabetes overlap on a number of levels.
Among endocrine and neurotransmitter  changes are  a  lower concentration of  catechola‐
mines, primary serotonin (Kuzmiaková et al., 1998), stimulation of the production of glu‐
cocorticoides,  growth hormone and glucagon, which work counter-regulationally against
the  hypoglycaemic  effect  of  insulin.  Increased levels  of  cortisol  are  observed equally  in
patients with diabetes and depression, similarly glucose intolerance disorder and the ori‐
gin  of  insulin  resistance  (Lustman et  al.,  2000).  In  many  patients  with  depression,  glu‐
cose intolerance linked with hyperinsulinemia and insulin resistance develops (Okamura
et al.,  2000). According to Zimmet et al. (1991) metabolic changes with depression evoke
the destabilization of a preexisting metabolic imbalance in individuals with a risk of de‐
veloping type 2 diabetes.  An abnormality of  serotonergic neurotransmission localized in
pre-synaptic and post-synaptic areas plays an important (thought not the only one) role
in the pathogenesis of depression (the so-called serotonin hypothesis of depression). Sub‐
stances which have a serotonergic effect (serotonin precursors,  fenfluramine, SSRIs) con‐
ditioned a clinically significant improvement in depressive symptoms. In this association
the  results  of  human  studies  are  known:  6  weeks  of  issuing  certain  SSRIs  (paroxetine,
fluoxetine and sertraline) to patients with both depression and diabetes led to a drop in
weight,  a  fall  in  triglycerides  and  cholesterol  in  the  blood,  a  drop  in  HbA1c  and  im‐
proved compliance (Talbot & Nouwen, 2000; Rubin & Peyrot, 2002).The positive effect of
serotonergic substances on depressive mood as well  as on a number of disease parame‐
ters of diabetes points to a possible etiological relationship.
The conjoined occurrence of depression and diabetes is not a chance phenomenon which
evokes consideration about their possible relationship. Scientific authorities present several
hypothetical interpretations: 1. Depression arises as a primary consequence of neurochemi‐
cal – biochemical changes which associate with diabetes; 2. Depression is a consequence of
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psychosocial factors which associate with the disease or its treatment; 3. Depression is an in‐
dependent risk factor for the origin of diabetes.
3.1. Depression with diabetes: result of biochemical factors
Current knowledge supports the presence of a relationship between depression, depressive
symptoms and possible growth of the risk for the development of type 2 diabetes. In con‐
trast, type 1 diabetes leads to the later development of depression. Kovacs et al. (1997) deter‐
mined that the first year from the origin of type 1 diabetes was the most risky for the origin
of depression. Lustman et al. (1988) observed that the values of glycaemia in individuals
with DM improve simultaneously with improvements in remission of depression. In dou‐
ble-blind randomized studies the hypoglycemic effect of antidepressant treatment was con‐
firmed. The origin of depression is a later result of type 2 diabetes, but depression can
increase the risk of its development. Results are similar for type 1 diabetes. Control of DM
improves simultaneously with the remission of depression, but also without a clear explana‐
tion of the mechanism for this assumption.
Depressive phases are more common in individuals with diabetes (Fava & McGratth, 2003,
Berken et al., 1984) and have longer duration (Bogner et al., 2007). In a 5-year monitoring
Lustman et al. (1988) found that in 22 of 28 patients with diabetes the occurrence of some
kind of depressive disorder was found, while depression was not manifested in only 2 of 20
individuals with diabetes. No differences between type 1 diabetes and type 2 diabetes in this
regard were observed. According to all, a longer duration of the depressive phase is more
associated with type 1 diabetes, although the differences between type 1 diabetes and type 2
diabetes were not observed in relation to inducing remission after the first depressive epi‐
sode. Peyrot & Rubbin (1989) also observed a longer duration of depressive symptoms in
245 individuals with type 1 diabetes and type 2 diabetes during a 6-month study, and 73%
were identified as having depressive symptoms. On the other hand Lustman et al. (1988) did
not find any differences in relation to the course and length of duration of depression be‐
tween both types of diabetes. They found a higher risk for longer duration of depression on‐
ly in patients with type 2 diabetes who were not treated with insulin. Wellset al. (1993) did
not find any significant differences between the course and the duration of the depressive
phase in patients with or without a case history of type 1 diabetes or hypertension. It’s pos‐
sible to say that depression and depressive symptoms have a higher recurrence and dura‐
tion in patients with diabetes.
3.2. Depression with diabetes: the result of psychosocial factors in relation to DM
With an increasing number of complications in diabetes, the probability of depressive symp‐
toms is also higher (Peyrot & Rubbin, 1997). In a study carried out by Davis et al. (1988) it
was shown that the social consequence of existence with DM (e.g. on traveling, active leisure
time, relationships) is connected with an increased risk of mortality, although no causal as‐
sociation was demonstrated. A significant relationship was shown between overall and spe‐
cific social support and depressive symptoms with diabetes (Littelfield et al., 1990).
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The presence of positive family history of depression occurs more often in patients with de‐
pression in comparison with individuals with diabetes without depression (27 vs. 3%). De‐
pression in mothers was found as a specific risk factor for the origin of depression in their
children type 1 diabetes at a low age with (Downey & Coyne, 1990). Kovacs et al. (1997) did
not find any significant differences in relation to sex and the origin of depression, but young
women with diabetes had a 9-times higher risk for the recurrence of depression compared
with young men with diabetes.
3.3. Depression with diabetes: a risk factor for the origin and worsening course of the
result of DM
Brande & Egede (2008) followed the long-term impact of depression on the control of gly‐
caemia in more than 11,000 people with type 2 diabetes with an average age of 66 years with
relatively well controlled diabetes (HbA1c = 7.3%), while depression was identified in 6% of
the them. A significant relationship was consequently found between depression and con‐
trol of glycaemia by measuring the HbA1c values, which were persistently higher (on aver‐
age by 0.13, 95%CI, 0.03-0.22, p=0.008) with each measurement at 3 months during a 4-year
study of patients with diabetes and concurrent depression.
Akbaralya  et  al.  (in  Barclay,  2008)  monitored  more  than  5000  patients  age  41-61  years
with depressive symptoms from 1991 to 1993 and then again 6 years later by using the
30-item subscale General  Health Questionnaire;  metabolic  syndrome was determined on
the basis  of  criteria  from the National  Cholesterol  Education Program.  They found that
the  presence  of  metabolic  syndrome was  linked with  the  increased risk  of  possible  de‐
pressive  symptoms  (OR,  1.38,  95%CI,  1.02-1.96).  Central  obesity,  increased  triglycerides
and HDL (but not other components of metabolic syndrome) were predictors of manifes‐
tation  of  depressive  symptoms.  These  findings  are  thus  consistent  with  the  hypothesis
that  depressive  symptoms  could  be  a  consequence  as  well  as  the  reason  for  metabolic
syndrome.
In a study by Backes et al. (2007) of more than 11,000 women with gestation diabetes, de‐
pression was retrospectively found in up to 15.2% of women in the period of the last 6
months of gravidity up to a year after giving birth, versus only 8.5% of women without dia‐
betes. These findings support the existence of a relationship between the two diseases – dia‐
betes and depression – namely, that both are frequent during gravidity and after birth, and
it is relevant, that post-partum depression is treatable but often goes unrecognized. It is
known that women with diabetes (keeping in mind the (non)use of insulin) have during
gravidity approximately two-times the risk of depression arising versus women without
diabetes (OR 1.85 (95%CI)).This is similar with the occurrence of depression in women with
diabetes in the post-partum period (OR 1.69 (95%CI)).
We  can  say  that  particularly  late  rising  of  depression  could  be  the  result  of  micro  or
macrovascular changes,  and the origin of  depression often precedes predominately type
2 diabetes by a number of years.  The newest findings support the consideration regard‐
ing the reciprocal  interaction among depression and diabetes,  because depressive symp‐
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toms could increase the risk of  origin of  type 2 diabetes and the diabetic  complications
associated with it.
4. The treatment of comorbidity depression and diabetes
Referring to some evidence that depression has an adverse psychological impact than the
"well being" as a diabetes, we can say that the treatment of depression in diabetes can direct‐
ly improve the psychological as well as medical parameters. Improving depressive symp‐
toms and induce remission, the main objectives related to psychological parameters. The
treatment of diabetes involves improving glycaemic control and reducing the risk for the oc‐
currence of either short or long-term complications of diabetes and premature mortality.
Based on mainly anecdotal evidence and a handful of randomized controlled trials, monoa‐
mine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) are considered to
have a hyperglycaemic effect, which is in keeping with their noradrenergic and(or appetito‐
genic effects, while selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and
sertraline, are more likely to be anorectic, improve insulin sensitivity and reduce glucose
levels, probably because the central serotoninergic pathways are important in the regulation
of food intake and food preferences (Ismail, 2010).
The common mechanisms etiopathogenetic diabetes and depression to some extent high‐
lights the fact that intensive treatment of depression leads to improved disease manifesta‐
tions diabetes (eg. decrease glucose) and vice versa, effective treatment for diabetes
determines retreat depressive symptoms. Selective serotonin reuptake inhibitors (SSRIs -
sertraline, paroxetine, fluoxetine, fluvoxamine, citalopram) due to a beneficial effect on a
number of pathological parameters diabetes - decrease glucose levels, weight loss, decreased
serum cholesterol and triglycerides - and given the antidepressant effect comparable with
TCAs and MAOIs are in the treatment of depression in diabetes first-line drugs.
The use of TCAs in patients with diabetes is mainly limited to their cardiotoxicity. TCAs
may increase serum concentrations of glucose and increased craving for sweets. Considera‐
bly better is to use antidepressants - SSRIs or SNRIs later, while in patients with diabetes on
this treatment was demonstrated the hypoglycaemic effect. From the observation of about
2% of 40 000 patients (Derijks, Heerdink et al., 2008) that the use of antidepressants is associ‐
ated with an increased risk of hypoglycaemia, but if they are used in patients with diabetes
for more than 3 years, the risk of hypoglycaemia is almost three times, it is important to
monitor the symptoms of hypoglycaemia and blood glucose. The use of antidepressants was
associated with hyperglycaemia (ROR 1.52 (95% CI: 1.20 to 1.93) and hypoglycaemia (ROR
1.884 (95% CI: 1.4 to 2.42). Connection with hyperglycaemia was risky for antidepressants
with affinity for serotonergic reuptake transporter (Derijks, Meyboom et al., 2008), the pub‐
lished data show that in terms of impact on the metabolic parameters between SSRIs differ‐
ences. Paroxetine abdominal obesity leads to more frequent administration than other SSRI
antidepressants (Reader, Bjelland et al., 2006).
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The other antidepressants should mention bupropion, venlafaxine and nefazodone, which
are favorable for their pharmacological properties in terms of comorbid conditions also con‐
venient - to have a neutral effect on body weight and glucose metabolism. Among the nine
antidepressants especially in pursuit of their effects on the gastrointestinal, central nervous
system and sexual life come out with the best profile of bupropion and soon fluvoxamine
(Dewan, Ananad, 1999). Weight gain is a common adverse side effect of acute and long-term
treatment with antidepressants. TCAs and MAOIs are probably more common cause of
weight gain than SSRIs and newer antidepressants, except mirtazapine, which is in this re‐
spect between SSRIs and TCAs. Also, paroxetine causes higher weight gain compared to
other SSRIs preparation for longer-term therapy and bupropion or nefazodone cause less
weight gain over the longer-term treatment (Fava, 2000).
According to several studies being less effective in patients with depression and diabetes
mirtazapine, in view of a higher risk of gaining weight. The case study series of patients re‐
ceiving doses of mirtazapine and 15 mg were observed gain weight during 5 months 16 kg,
with obesity and by all important risk factor for glucose dysregulation (Fisfalen, Hsiung et
al., 2003).
TCAs (Carney, 1998) and MAOIs should be administered only as a last option (Nickelson,
Box, 1999) for the treatment of depression in patients with diabetes. TCAs are associated
with weight gain (Nakra, Rutland et al., 1977, Berken, Weinsthein et al., 1984) and taste the
sweet and carbohydrate (Paykel, Mueller et al., 1973, Harris, Young et al., 1984), which can
be problematic for patients with increased consumption of calories (Goodnick, Henry et al.,
1995, Carney 1998). TCAs can worsen hyperglycaemia and glycaemic control during longer
treatment (Nickelson, Box 1999, Carney, 1998) and their anticholinergic, cardiovascular and
musculoskeletal adverse side effects may worsen symptoms in relation to diabetes (consti‐
pation associated with diabetic gastroparesis) (Carney, 1998, Lane, 1993). MAOIs can aggra‐
vate hypoglycaemia and delay the restoration of normal glucose concentrations when taken
with insulin or sulfonylurea (Cooper & Ashrocft., 1966). In addition, treatment with MAOIs
is associated with weight gain and the need for strict dietary restrictions, which certainly
complicates the diet such as in patients with diabetes (Carney, 1998).
In 80 patients with depression Kopf, Westpal et al. (2004) observed values of lipoproteins,
insulin sensitivity and cortisol in saliva before and after 35 days of treatment with amitripty‐
line or paroxetine. The main findings were that patients with depression and weight in the
standard have insulin resistance corresponding to the HPA axis, overweight patients had to‐
tal and LDL cholesterol out of standard antidepressant treatment led to an improvement in
lipoprotein and cholesterol levels, changes in triglyceride metabolism affected by the treat‐
ment and weight three important factors control lipid parameters depending on the pres‐
ence of the metabolic state: weight, hypercorticolism and insulin resistance. This study first
examined the detailed lipid profile in patients with diabetes and depression.
Bupropion contrast in patients with diabetes suited to the fact that side does not sexual reac‐
tions and decreases body weight in obese patients had more than placebo (Jain, Kaplan et al.
2002). Lustman, Williams et al. (2007) in a group of 90 patients with type 2 diabetes and de‐
pression and taking over 16 months bupropion found decrease BMI, total fat, and HbA1c (p
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≤ 0.01 for all parameters). Reduction of BMI and severity of depression independently pre‐
dicted lower HbA1c after treatment of the acute phase of depression, while only reducing
the severity of depression (p≤0.001) affected on HbA1c with the passage of time. Sawhney et
al. (2007) observed the good effect of TCAs administered in low doses in depressed patients
suffering from chronic vomiting, did not respond to prokinetic therapy. Antidepressant du‐
loxetine is recommended for the treatment of diabetic neuropathy (Švestka, 2005).
Data from a large study of over 4800 patients with diabetes enrolled in a health maintenance
organization (HMO) found that approximately 70% of those with comorbid depression
(based on scoring ≥ 10 on the PHQ-9) had experienced affective symptoms for two years or
longer(Katon et al., 2004). Patients with diabetes tend to be older, and recent primary care
data have shown that the average length of an episode of depression in older primary care
patients is approximately 18 months, whereas in mixed-aged populations the mean length
of an episode is approximately 4 - 6 months (Vuorilehto et al, 2009).
The tendency for depressive symptoms to be chronic in patients with diabetes is also shown
by recent data from a five-year follow-up study of approximately 2700 patients with diabe‐
tes. Approximately 82% of patients who met DSM-IV criteria for major depression at five-
year follow-up had minor or major depression at baseline (Katon et al., 2009). Finally, the
recurrent course of depression was shown in a longitudinal study, which found that 79% of
patients with diabetes who had major depression relapsed over a five-year follow-up peri‐
od, with a mean of four episodes per patients (Katon, von Korff et al. 2004).
Several systematic reviews have been completed exploring effect sizes of psychotherapeutic
as well as pharmacological treatments of patients with comorbid depression and diabetes
(Petrak 2009; van der Feltz-Cornelis et al. 2010). Efficacy trials generally evaluate intensive
treatment of a carefully selected patient group by highly trained staff. Patients with clinical‐
ly significant psychiatric comorbidities, such as panic disorder of medical comorbidities, are
often excluded from these trials. An important question for researchers and clinicians is
whether evidence-based pharmacotherapies and psychotherapies that have proven effective
in populations of patients with depression with minimal medical illness would be as effica‐
cious in patients with diabetes.
A systematic review of efficacy trials performed in 2009 yielded 11 randomized clinical tri‐
als, five on psychotherapeutic interventions and six on pharmacological treatments. Most
trials were small, with only one recruiting more than 100 patients and the others including
60 or fewer patients. Most trials were completed on patients with type 2 diabetes with seri‐
ous depressive symptoms or major depressive disorder, and effect sizes were specified for
depressive symptom severity as well as for glycaemic control.
4.1. Pharmacological studies
As shown Table 4, the pharmacotherapeutic interventions had moderate effects on depres‐
sive symptoms, and small effects on glycaemic control. The effect on depressive outcomes
was very similar, but the effect on glycaemic control was smaller than that of the psycho‐
therapeutic studies, many of which had explicit interventions aimed at improving glycaemic
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control. The pharmacologic trials were also small, mostly under 100 patients enrolled. The
small numbers of patients enrolled in both psychotherapy and pharmacologic efficacy trials
limits the generalizability of the findings.
Study N (completers),
diabetes type,
mean age
Intervention
conditions,
follow-up (FU)
Outcome assessment (depression,
diabetes
Effect size
Lustman et al.,
1997b
N=28, type 2-50%
49-49,2ys
nortriptyline vs
placebo,FU- 9 ws
Depression: BDI (p=0.03), DM: HbA1c,
n.s., no outcome reported
Depression: Δ
-0.868, DM: Δ 0
Lustman et al.,
2000
N=54,type 2- 56%
45-47ys
fluoxetine vs
placebo, FU- 8 ws
Depression: HAMD (p<0.04), DM:
HbA1c (p=0.13, n.s.)
Depression: Δ
-0.573, DM: Δ 0.419
Paile-Hyvärinen et
al., 2003
N=13, type
2-100%, 61-62ys
paroxetine vs
placebo, FU- 4ws
Depression: MADRS (p=0.25,ns.),
DM:GHbA1c (p=0,08, n.s.)
Depression: Δ -0.68,
DM: Δ 1.07
Xue et al., 2004 N=48, type 2-85%,
21-65ys
paroxetine vs
placebo
Depression: HAMD-17 (p<0.01), DM:
HbA1c (p=0.25, ns.)
Depression: Δ -0.78,
DM: Δ 0.34
Gülseren et al.,
2005
N=23, type 2-
100%, 58ys
fluoxetine vs
paroxetine
Both groups improved –HDRS
(p=0.003, s.f.), HbA1c – n.s. both
No significant
difference between
the two conditions
Lustman et al.,
2006
N=152, type 2-
65%, N/A
sertraline (flexible
doses) vs placebo
n. s. between groups
Paile-Hyvärinen et
al., 2007
N=49, type 2-
100%, 59ys
paroxetine vs
placebo
Depression: HADS (p=0.45, n.s.), DM:
HbA1c (p=0.7, n.s.)
Depression: Δ -0.26,
DM: Δ 0.14
Table 4. Overview of the most important trials with antidepressant treatment under: BDI-Beck Depression Inventory,
HAMD-Hamilton Asberg Montgomery Depression Scale, ns- no significant
Due to the lack of data in our conditions in relation to the comorbidity of depression and
disorders related to glucose and lipid metabolism and at the same time of the presented
high prevalence independently existing of these disorders, we decided to work-up a pilot
study on the impact of antidepressants primarily on glucose and lipid metabolism in pa‐
tients with depression. We found changes in lipid – HDL, LDL, triglycerides, glucose,
HbA1c and BMI parameters in patients with depression during antidepressive treatment
without diabetes. The assess changes of treatment with two groups of antidepressants –
SSRI´s and SNRI´s in flexible doses. It was prospective study of outpatients and in-patient’s
file hospitalized at the 1st Dept. of Psychiatry University Hospital and University of P. J. Ša‐
fárik, Košice (2010 – 2011). Hypothesis was that SSRI´s and SNRI´s do not deteriorate theese
metabolic parameters, HbA1c will be decrease, HDL will be increase and compare the dif‐
ferences between groups. After six months 74 patients completed follow-up ( 65% women
with MDD, DSM-IV ). We used scales: MADRS, Beck Anxiety Inventory, Zung Depression
Scale, statistical program IBM SPSS (version 20. 0). The consent to research granted Ethics
committee of School of Medicine of University of P. J. Šafárik in Košice.
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Scale GroupsSSRI´s/SNRI´s N Mean
Beck Anxiety Inventory - baseline SSRI/SNRI 38/36 23,29/ 24,14
Beck Anxiety Inventory - final SSRI/SNRI 38/36 15,18*/16,50*
Zung Depression Inventory- SDS-
baseline
SSRI/ SNRI 38/36 67,26/ 66,83
Zung Depression inventory – final
SSRI/SNRI 38/36 49,39*/ 52,44*
I
MADRS baseline SSRI/SNRI 38/36 37,21/ 36,89
MADRS final 1 SSRI/SNRI 38/ 36 16,95*/ 17,89*
BMI baseline SSRI/SNRI 38/ 36 25,54/ 26,76
BMI final SSRI/SNRI 38/ 36 26,22/ 27,1
* the mean difference is significant at the,05 level
Table 5. Score in some scales
In both groups dominated by women (three times) – 27/9 (SSRI´s group); 28/10 (SNRI´s
group) and on the other hand, less presumptive SNRI medication type were deployed glob‐
ally in patients with a higher mean age (SNRI´s = 52,7/28-73/; SSRI´s = 41,7 /20-64/). There
was an improvement in the scales in both groups: MADRS, Beck Anxiety Inventory, Zung
Depression Scale (s. f., table 5). Similar, the results in study Songar et al. (1993) indicate that
some relations exist between anxiety and the worsening of metabolic control (mainly in
HbA1c). The HDL cholesterol values have improved after six months antidepressive treat‐
ment in both groups (1.31 vs 1.4 /SNRI´s/ 1.38 vs 1.5 /SSRI´s/), which corresponds to the data
Svačina et al. (2006) and Hardy et al. (2007). These findings are particularly important be‐
cause from this one that is most closely connected with cardiovascular risks play mainly
LDL and HDL components. The triglycerides values have improved statistical significant af‐
ter six months SSRI treatment vs SNRI treatment (Mann-Whitney U=496,000 Asymp. Sig. (2-
tailed)=0.042 = p≤0.05), which correlates with the monitoring Flechtner-Mors (2008) also in
SSRI preparations, which is important from the point of view that higher levels of triglycer‐
ides are considered primary in the aetiology of disorders that are related to oxidative stress
and increased levels of LDL. As we expected, HbA1c improved in the SNRI´s (5.55 vs 5.24,
n. s.) and SSRI´s group (5.23 vs 5.18, n. s.) which corresponds with the results of several
pharmacological studies (Lustman et al., 1997b, 2006; Gülseren et al., 2005). On the other
hand can not draw definite causal conclusions regarding the limitations on file size and es‐
pecially the length of the monitoring itself. We confirmed the hypothesis that SSRI´s and
SNRI´s do not deteriorate metabolic parameters – HDL, LDL, triglycerides, HbA1c, BMI,
even HbA1c will be decrease (n. s.), HDL will be increase (n. s.), triglycerides were im‐
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proved in SSRI´s group (s. f.), but in addition the differences between groups we didn´t find
similar as Gülseren et al. (2005).
4.2. Psychotherapeutic interventions
The effect size of the psychotherapeutic interventions were moderate to large for improve‐
ment of depressive symptoms, and moderate to large for improvement of glycaemic control.
Three of the five psychotherapy trials compared an evidence-based depression psychothera‐
py and diabetes education to diabetes education alone. Therefore, it is unclear whether im‐
provements in glycaemic control were due to the beneficial effect of the depression-focused
psychotherapy or the combination of both depression therapy and diabetes education.
Study N (completers),
diabetes type,
mean age
Intervention conditions, follow-up
(FU)
Outcome assessment
(depression, diabetes
Effect size
Lustman et
al., 1998
N=41, type
2-100%,
53-56,4ys
CBT+ diabetes education vs diabetes
education alone, FU- 11ws
Depression: BDI
(p<0.001)in CBT group,
DM: HbA1c in CBT group
(p<0.03)
Depression: Δ
-1.112, DM: Δ
-0.704
Huang et al.,
2002
N=59,type 2-
100%, N/A
Antidiabetics + diabetic education +
psychological +relaxation vs
antidiabetics only, FU- 3mo
Depression: SDS (p<0.05),
DM: HbA1c (p<0.05)
Depression: Δ
-0.521, DM: Δ
-0.521
Li et al., 2003 N=120, N/A,
50,5-52,3ys
Antidiabetics + diabetic education +
psychological treatment vs
antidiabetics only, FU- 4ws
Depression: SDS (p<0.01),
DM: FBG(p<0.05)
Depression: Δ
-0.478, DM: Δ
-0.362
Lu et al., 2005 N=60, type
2-100%, 65ys
Diabetes and CVA education +
electromyographic treatment +
psychological treatment vs usual
care, FU- 4ws
Depression: HAMD-17
(p<0.01), DM: FBG
(p<0.05)
Depression: Δ
-0.688, DM: Δ
-0.517
Simson et al.,
2008
N=30, type 2-
80%, 60,5ys
Individual supportive psychotherapy
vs usual care, FU- discharge (3-20ws)
Depression: HADS
(p=0.018), DM: PAID
mean (p=0.008)
Depression: Δ
-0.918, DM: Δ
-1.043
Table 6. Overview of the most important trials with psychotherapeutic interventions under table: CBT - Cognitive-
behavioral therapy, BDI- Beck Depression Inventory
5. Discussion
The probability of the occurrence of depression in patients with diabetes is higher, because
depression in patients with diabetes is often unrecognized and therefore also untreatable
and the association between depression and glycaemic control is small in cross-sectional
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studies and almost disappears in most of the handful of prospective studies (Lustman et al.,
2000a). It is interesting that complications associated with diabetes and mortality are already
observed with less serious depressive displays (Black et al., 2003). The comorbidity of de‐
pression and obesity worsens the course of diabetes, and furthermore, depression worsens
the adherence to a diabetic diet and treatment and predicts low compliance in diabetological
programs (McKellar et al., 2004). From the results of several studies (Katon et al., 2004) it
follows that the relationship between depression and obesity runs in both directions. From
several studies it follows that the course of depression in individuals with diabetes is not
causally dependent on diabetes. Depression in individuals with diabetes represents a more
complex phenomena following from interactions between genetic, biological and psychoso‐
cial factors, which could significantly influence the recurrence and longer duration of de‐
pression. In the case of type 2 diabetes it is unlikely that the first episode of depression
would be as a consequence of diabetes. The development of depression often precedes the
manifestation of type 2 diabetes by many years. Depressive symptoms could increase the
risk of development of type 2 diabetes and its complications. It is shown that depression
ranks among the most important risk factors for the development of type 2 diabetes and is
not merely a secondary emotional response to a chronic and complicated bodily illness, but
that an independent risk factor for the origin of type 2 diabetes is involved (Lustman et al.,
2006). Despite all, we today still do not have sufficient proof about confirmation of the hy‐
pothesis relating to the occurrence of depression as a consequence of biochemical changes
following directly from diabetes or its treatment or from psychological factors. But these fac‐
tors can influence the increasing of insulin resistance and the reduction of glucose as a result
of changes during depression.
6. Conclusion
The occurrence of depression with bodily diseases represents an unfavorable prognostic in‐
dicator. It worsens the therapeutic response and the course of the bodily disease, makes re‐
gaining health and rehabilitation more difficult, prolongs hospitalization, weakens the
ability of the ill individual to care for his or her own needs, represents a risk of suicidal be‐
haviour and as a final consequence increases the costs for treatment and demands on the
health care system. Its timely recognition and adequate treatment are exceptionally impor‐
tant. Depression in patients with diabetes mellitus represents a complex phenomenon which
is the result of complicated interactions between biological, genetic and psycho-social fac‐
tors. There has been the hypothetical assumption that depression originates as a direct con‐
sequence of neurochemical changes with diabetes mellitus. More proof, however, supports
the so-called inverse hypothesis, according to which depression represents a risk for the ori‐
gin of type 2 diabetes mellitus as well as its complications.
The fact that intensive treatment of depression leads to improved disease displays of diabe‐
tes (e.g. a drop in glucose levels) and the reverse, that effective treatment of diabetes condi‐
tions the regression of depressive symptoms, points to common etiopathogenic mechanisms
to a certain measure point. There is high prevalence of depressive and anxiety disorders in
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patients with diabetes, and these disorders adversely affect diabetes self-care, disease con‐
trol and clinical outcomes. Complications of diabetes resulting in functional impairment can
also precipitate a depressive episode. Efficacy data have demonstrated that both evidence-
based psychotherapies and pharmacotherapies are effective treatment modalities for depres‐
sion in patients not only with diabetes. The choice of antidepressant medication for the
patient with diabetes and depression remains one in which the clinician needs to individual‐
ize therapy to the specific needs of the patient. There are strong data showing that the spe‐
cific initial choice of antidepressant, with the aforementioned exceptions, may be less crucial
than the duration of appropriate therapy, the coordination of psychiatric and medical care,
and the input of the clinician in modification of dose or choice of medication dependent
upon the response to therapy. The patient´s tolerance to a specific antidepressant is not pre‐
dictable, in part due to genetic variations in the metabolism of specific medications, as well
as other less well studied aspects of biologic variability.
To what measure treatment of comorbid depression reduces morbidity and mortality of dia‐
betes mellitus and to what measure treatment influences the unfavorable consequences of
depression still remain an open question.
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